Latest HVIVO Press Release: 17.06.19 hVIVO RSV challenge model delivers positive results for novel therapy
MENUMENU
  • Services
        • Human challenge full-service solution
        • human challenge full service solution

          Industry leading provider of viral challenge studies

          • See Our Solution
        • hVIVO Challenge Models
          • Influenza
          • RSV
          • HRV
          • Asthma
          • COPD
          • Cough
        • Laboratory Services
          • Virology
          • Immunology
          • Biomarkers
  • Investors

        • Investors

          hVIVO’s shares are listed on the AIM market of the London Stock Exchange under the HVO ticker.

          This area is dedicated to keeping shareholders and potential investors informed.

        • Regulatory News
        • Presentations & Webcasts
        • Financial Reports
        • Financial Calendar
        • Governance
        • Shareholder Information
        • Share Price Info
        • Analyst Coverage
        • Advisers
        • Aim Rule 26
        • RNS Email Alerts
  • News, Media & Events

        • News, Media & Events

          A source for the latest press releases, scientific publications and other media as well as details of investor and scientific events that we attend and host across the world.

          • Latest News & Updates
        • Press Releases
        • Other Company News
        • Videos
        • Events

        • LATEST NEWS

          hVIVO is Gold Sponsor and presenter at World Vaccine Congress, Washington DC, USA April 2019
  • About Us

        • About Us

          Our Mission is to build a profitable clinical development services business supporting product development for our clients through human challenge studies to establish early proof of concept.

          • More about hVIVO
        • Overview
        • Board of Directors
        • Executive Leadership Team
        • Imutex Joint Venture
        • Scientific Papers
        • Quality Commitment
        • Ethics & Compliance
        • img

          LATEST PRESS RELEASE

          17.06.19 hVIVO RSV challenge model delivers positive results for novel therapy

        • UPCOMING EVENTS

          Options X28 Aug - 01 Sep, Singapore, Asia
  • Volunteers
  • Careers
  • Contact Us

Medivir licenses Respiratory Syncytial Virus drug program from Boehringer Ingelheim – WSJ.com

August 5, 2014 11:28 am

https://online.wsj.com/article/PR-CO-20140804-901143.html

Follow @hVIVO_UK

Comments are closed here.

Whether you’re a potential customer, job seeker, health professional or an investor, you can find the best way to contact us from the list below.

Contact Us
  • Terms & Conditions
  • Careers
  • Sitemap
© 2019 Copyright hVIVO Services Limited. All rights reserved.
Privacy Policy | Cookie Policy